[English]  [Pусский]  [中文]  
 
ctt-journal > Ptushkin et al. abstract

Ptushkin et al. abstract


Please cite this article as follows:
Ptushkin VV, Afanasyev BV, Zhukov NV, Uss AL, Karamanesht EE, Milanovich NF, Mikhaylova NB, Korenkova IS, Minenko SV, Demina EA, Zmachinski VA, Pugachev AA, Borodkin SV. Efficacy and safety of high-dose chemotherapy with autologous hematopoietic stem cell rescue for relapsed/refractory Hodgkin's lymphoma patients in former USSR countries. Retrospective analysis of data from four transplantation centers in Belarus, Russia and the Ukraine. Cell Ther Transplant. 2008;1:e.2008-05-30-002-en. doi:10.3205/ctt2008-05-30-002-en

 

Efficacy and safety of high-dose chemotherapy with autologous hematopoietic stem cell rescue for relapsed/refractory Hodgkin's lymphoma patients in former USSR countries. Retrospective analysis of data from four transplantation centers in Belarus, Russia and the Ukraine

Ptushkin VV, Afanasyev BV, Zhukov NV, Uss AL, Karamanesht EE, Milanovich NF, Mikhaylova NB, Korenkova IS, Minenko SV, Demina EA, Zmachinski VA, Pugachev AA, Borodkin SV

Running title: HDC in patients with HL in former USSR republics.

Summary

High-dose chemotherapy (HDC) with autologous stem cell transplantation support is a routine treatment approach for relapsed or refractory Hodgkin's lymphoma (HL) patients. Unfortunately, HDC is much less common in the former USSR republics; among other reasons due to a lack of information about the efficacy and safety of this treatment as performed at local centers.

We analyzed the outcome for 184 HL patients receiving HDC in the former USSR republics between January 1990 and March 2003. Most patients had primary refractory disease (44.8%), early (27.2%) or multiple (21.6%) relapses. Restaging revealed stage III–IV disease in 69%, and B-symptoms in 53% of cases. The patients received a mean of 9 (2 to 34) courses of standard chemotherapy prior to HDC.
HDC yielded complete response or complete response uncertain (CR/CRu) in 68.2% of cases, and the 5-year overall survival (OS) rate was 60%; freedom from treatment failure (FFTF) survival was 41.5% with a median follow-up of 30 months (3 to 139 months). As estimated with respect to disease status, the 5-year FFTF was 35% among patients with primary refractory disease, 46.4% in patients with multiple relapses, and 59.2% in patients with early sensitive relapse. The early death rate was 5.4%, but has demonstrated a considerable decreasing trend over recent years (1.4% in 2000–2003). The HDC with autologous hematopoietic stem cell rescue procedure performed at transplant centers in the former USSR republics is associated with low mortality and satisfactory FFTF for patients with primary refractory or relapsed Hodgkin's disease.

Keywords: Hodgkin’s lymphoma, relapse, primary refractory disease, high-dose chemotherapy, stem cell support


Please cite this article as follows:
Ptushkin VV, Afanasyev BV, Zhukov NV, Uss AL, Karamanesht EE, Milanovich NF, Mikhaylova NB, Korenkova IS, Minenko SV, Demina EA, Zmachinski VA, Pugachev AA, Borodkin SV. Efficacy and safety of high-dose chemotherapy with autologous hematopoietic stem cell rescue for relapsed/refractory Hodgkin's lymphoma patients in former USSR countries. Retrospective analysis of data from four transplantation centers in Belarus, Russia and the Ukraine. Cell Ther Transplant. 2008;1:e.2008-05-30-002-en. doi:10.3205/ctt2008-05-30-002-en 

Full text
<-- Previous abstract        Contents        Next abstract -->
<-- Предыдущее резюме   Oглавление     Cледующее резюме -->